NNVC

Nanoviricides Inc. (NNVC) | Rumor.io

Nanoviricides

NNVC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,975

Bullish sentiment (50-day avg)87%

Price to earnings ratio-2.38

Market capitalization38.3M

Earnings per share-0.44

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-9.5M

Social

What share of all stock conversation is about NNVC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 21

The company NanoViricides, Inc. (NNVC) is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.
The drug's efficacy could result in a stock price of $58-$116, according to some analysts.
The stock price of NNVC has seen significant increases in recent days, with a 14% gain and a 24.3% increase in one day, with the author predicting further upside.

Generated by AI

Sentiment

Of the messages about NNVC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -43.75	86.84%	94.43% +10.26
Bearish	0%	50% +43.75	13.16%	5.57% -10.26

Bullish· May 27

$NNVC buyers are stepping in, with a strong run and significant volume boost, indicating a potential rebound.
The stock has shown resilience, dipping only 7.93% before finding support at $1.500, with resistance at $1.640 and a bullish RSI reading.
$NNVC is expected to climb further, with predictions of a 2% or more increase, and some analysts even anticipating a close above $4.00 today.

Bearish· May 27

$NNVC has no viable product that has been tested on humans, making its prospects uncertain.
The company's lack of human testing raises concerns about its ability to deliver on its claims, potentially leading to a disappointing outcome.
$NNVC's past performance suggests it may be a pump and dump scheme, with the current price surge potentially setting the stage for a significant decline.

Generated by AI

Topics

Of the messages about NNVC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	74.32%
Technical Analysis	—	0%	0%	19.62%
Analysts	—	0%	0%	1.44%
Controversies	—	0%	0%	2.23%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	2.39%

Announcements· May 27

NanoViricides, Inc. ($NNVC) is a clinical-stage antiviral biotech developing broad-spectrum nanomedicine treatments, with its lead antiviral candidate NV-387 advancing toward Phase II trials.
NV-387 has received FDA Orphan Drug Designation and is positioned as a superior treatment option for Ebola, with NanoViricides stating it is ready to be shipped to the DRC.
The company's focus on NV-387 has contributed to a 37% increase in $NNVC's stock price premarket, driven by its potential as a broad-spectrum antiviral treatment.

Technical Analysis· Jun 25

$NNVC is currently at a potential R/R area, with a key level at $2.10 and a possible upside move to $3.50 if it breaks above $2.11.
The stock has shown a high accumulation stage and strong buying interest, with the OBV indicator remaining relatively high, suggesting a positive sign for the stock.
$NNVC is forming a huge bull flag, with a next big resistance point at $3.30, and is expected to bounce off the bottom with some volume, potentially reaching $2.40-$2.60 or even $3.60.

Generated by AI

Community

Of the messages about NNVC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	31.25%	42.86%	47.77%
Newcomers	50%	68.75%	57.14%	52.23%

Regulars· Aug 5

The company's monkeypox treatment plans were announced, leading to a 41% surge in shares.
Regulars point to the historical trend of piggybacking infectious diseases as a thesis that played out as expected.
The RSI indicator for NanoViricides has left the overbought zone, and the Aroon indicator has entered an uptrend.

Newcomers· May 27

Newcomers are focusing on NanoViricides' lead antiviral candidate NV-387, which is advancing toward Phase II trials and has received FDA Orphan Drug Designation.
The company's recent momentum is tied to its broad-spectrum nanomedicine treatments and its potential to address the ebola virus.
Buyers are stepping in to purchase shares of NanoViricides, with some expecting a strong run, but others are cautious about a potential pullback.

Generated by AI

SHELTON, CT / ACCESS Newswire / September 29, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, September 28, 2026.

23h agoYahoo! Finance Canada

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

6d agoYahoo Finance

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides

SHELTON, CT / ACCESS Newswire / September 15, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") is scheduled to start next week at an Ebola Treatment Center in the Ituri province.

14d agoYahoo Finance

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

SHELTON, CT / ACCESS Newswire / August 31, 2026 / , Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program.

29d agoYahoo Finance

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin ...

1mo agoYahoo Finance

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin ...

2mo agoca.finance.yahoo.com

Also Discussed

Investors talking about NNVC also mention

#	Name	Attention
1	Co-Diagnostics Inc.CODX	0%+0
2	YTEN - Yield10 Bioscience, Inc.	——
3	Genprex Inc. Common StockGNPX	0%0
4	Aethlon Medical, Inc.AEMD	0%new
5	Zivo Bioscience Inc.ZIVO	0%0
6	BIMI - BIMI International Medical Inc.	——
7	ASLN - ASLAN Pharmaceuticals Limited	——
8	VXRT - Vaxart, Inc.	——
9	Inovio Pharmaceuticals Inc.INO	0%+0
10	Viveve Medical Inc.VIVE	0%0

Nanoviricides Inc.

Healthcare
Biotechnology

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells. Its lead candidate, NV-387, is being developed for multiple viral infections, including respiratory viruses and other high-priority infectious diseases. NanoViricides also maintains additional antiviral programs addressing conditions such as herpes and other viral threats. The company combines drug discovery, development, and commercialization capabilities within a single business model, supporting its efforts across research, preclinical work, and clinical development. Headquartered in Shelton, Connecticut, NanoViricides occupies a niche position in the healthcare market as a developer of specialized antiviral treatments aimed at complex viral diseases.

Website

Location

1 Controls Drive

Shelton, CT, 06484

United States

Social

What share of all stock conversation is about NNVC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 21

The company NanoViricides, Inc. (NNVC) is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.
The drug's efficacy could result in a stock price of $58-$116, according to some analysts.
The stock price of NNVC has seen significant increases in recent days, with a 14% gain and a 24.3% increase in one day, with the author predicting further upside.

Generated by AI

Sentiment

Of the messages about NNVC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -43.75	86.84%	94.43% +10.26
Bearish	0%	50% +43.75	13.16%	5.57% -10.26

Bullish· May 27

$NNVC buyers are stepping in, with a strong run and significant volume boost, indicating a potential rebound.
The stock has shown resilience, dipping only 7.93% before finding support at $1.500, with resistance at $1.640 and a bullish RSI reading.
$NNVC is expected to climb further, with predictions of a 2% or more increase, and some analysts even anticipating a close above $4.00 today.

Bearish· May 27

$NNVC has no viable product that has been tested on humans, making its prospects uncertain.
The company's lack of human testing raises concerns about its ability to deliver on its claims, potentially leading to a disappointing outcome.
$NNVC's past performance suggests it may be a pump and dump scheme, with the current price surge potentially setting the stage for a significant decline.

Generated by AI

Topics

Of the messages about NNVC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	74.32%
Technical Analysis	—	0%	0%	19.62%
Analysts	—	0%	0%	1.44%
Controversies	—	0%	0%	2.23%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	2.39%

Announcements· May 27

NanoViricides, Inc. ($NNVC) is a clinical-stage antiviral biotech developing broad-spectrum nanomedicine treatments, with its lead antiviral candidate NV-387 advancing toward Phase II trials.
NV-387 has received FDA Orphan Drug Designation and is positioned as a superior treatment option for Ebola, with NanoViricides stating it is ready to be shipped to the DRC.
The company's focus on NV-387 has contributed to a 37% increase in $NNVC's stock price premarket, driven by its potential as a broad-spectrum antiviral treatment.

Technical Analysis· Jun 25

$NNVC is currently at a potential R/R area, with a key level at $2.10 and a possible upside move to $3.50 if it breaks above $2.11.
The stock has shown a high accumulation stage and strong buying interest, with the OBV indicator remaining relatively high, suggesting a positive sign for the stock.
$NNVC is forming a huge bull flag, with a next big resistance point at $3.30, and is expected to bounce off the bottom with some volume, potentially reaching $2.40-$2.60 or even $3.60.

Generated by AI

Community

Of the messages about NNVC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	31.25%	42.86%	47.77%
Newcomers	50%	68.75%	57.14%	52.23%

Regulars· Aug 5

The company's monkeypox treatment plans were announced, leading to a 41% surge in shares.
Regulars point to the historical trend of piggybacking infectious diseases as a thesis that played out as expected.
The RSI indicator for NanoViricides has left the overbought zone, and the Aroon indicator has entered an uptrend.

Newcomers· May 27

Newcomers are focusing on NanoViricides' lead antiviral candidate NV-387, which is advancing toward Phase II trials and has received FDA Orphan Drug Designation.
The company's recent momentum is tied to its broad-spectrum nanomedicine treatments and its potential to address the ebola virus.
Buyers are stepping in to purchase shares of NanoViricides, with some expecting a strong run, but others are cautious about a potential pullback.

Generated by AI

Nanoviricides

Social

Sep 21

Bullish· May 27

Bearish· May 27

Announcements· May 27

Technical Analysis· Jun 25

Regulars· Aug 5

Newcomers· May 27

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Also Discussed

Nanoviricides Inc.

Company Information

Location

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Also Discussed

Social

Sep 21

Bullish· May 27

Bearish· May 27

Announcements· May 27

Technical Analysis· Jun 25

Regulars· Aug 5

Newcomers· May 27

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides